Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CAVA Group Inc (CAVA) vs Twist Bioscience Corp (TWST) Price & Performance

CAVA Group IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

CAVA Group Inc vs Twist Bioscience Corp — how do they compare? CAVA Group Inc trades at $67.5 (market cap $7.17B), while Twist Bioscience Corp trades at $122.96 (market cap $7.82B). The key difference: CAVA Group Inc and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, CAVA Group Inc nearer its low. Which is the better fit depends on your goals.

CAVATWST
Market Cap
$7.17B$7.82B
Sector
Consumer CyclicalHealth
52-Week High
$97.39$124.88
52-Week Low
$43.59$24.16
Enterprise Value
$7.32B$7.75B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CAVA Group Inc

CAVA trades at $62.42, up 0.31% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $1.18B in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights anticipation for the Q2 2026 earnings report, with analysts citing strong traffic and expansion as positive catalysts.

Wall Street maintains a bullish outlook with a consensus price target of $91.00, though high valuation multiples and recent net cash outflows pose risks. The stock's investment case hinges on continued execution of its growth strategy amid competitive industry pressures.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.

The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About CAVA Group Inc

CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.

Read more on CAVA

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST